Amyl Therapeutics

Amyl Therapeutics is pioneering a new approach to treating neurodegenerative diseases. By developing novel therapies that recognize and target multiple misfolded proteins, they aim to make a transformative impact on the lives of patients affected by Alzheimer’s, Parkinson’s, and other diseases caused by protein misfolding.

Amyl Therapeutics is an affiliate of Proclara launched in 2020 and based in Belgium. Amyl Tx is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, they aim to make a transformative impact on the lives of patients affected by systemic amyloidosis.